| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
CYP2
The primary targets of MS-PPOH are CYP2C8 and CYP2C9, cytochrome P450 epoxygenases that catalyze the conversion of arachidonic acid to epoxyeicosatrienoic acids (EETs). MS-PPOH inhibits CYP2C8 with an IC50 of 15 μM and CYP2C9 with an IC50 of 11 μM. By inhibiting these enzymes, MS-PPOH blocks the formation of EETs, which are important mediators of vascular tone, inflammation, and renal function. |
|---|---|
| ln Vitro |
MS-PPOH prevents the formation of EET in cells. MS-PPOH diminishes the 11,12-EET (1.0 μM)-induced cell motility and prevents invasion and migration of basal (tonic) cells[1].
In vitro, MS-PPOH selectively inhibits CYP2C8 (IC50 = 15 μM) and CYP2C9 (IC50 = 11 μM). The compound is used as a tool to study the role of epoxygenase-derived metabolites in various biological processes. By blocking EET formation, MS-PPOH allows researchers to investigate the physiological roles of these metabolites in vascular tone regulation, inflammation, and renal function. |
| ln Vivo |
Dahl salt-resistant rats on 2% NaCl drinking solution had significantly lower renal levels of epoxyeicosatrienoic acids (EETs) after 6 days of treatment with MS-PPOH (20 mg/kg/day, iv)[3].
In vivo, MS-PPOH is used to study the physiological roles of epoxygenase-derived metabolites in cardiovascular and renal function. By inhibiting CYP2C8 and CYP2C9, the compound blocks the formation of EETs, which are important mediators of vascular tone, inflammation, and renal function. MS-PPOH has been applied in cardiovascular and renal research to dissect the roles of epoxygenase-derived metabolites. |
| Enzyme Assay |
The in vitro enzyme assay for MS-PPOH involves measuring the inhibition of CYP2C8 or CYP2C9 epoxygenase activity using recombinant enzyme or liver microsomal preparations. The assay is performed in a suitable buffer system containing NADPH as a cofactor and arachidonic acid as a substrate. Test compounds are incubated with the enzyme and substrate at various concentrations, and the formation of EETs is measured using HPLC or mass spectrometry. IC50 values are calculated by fitting dose-response curves to the inhibition data.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: PC -3 cells Tested Concentrations: 2.0 and 10.0 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited tonic (basal) cell invasion and migration. Cellular assays for MS-PPOH typically use vascular endothelial cells, renal cells, or other cell types that express CYP2C8 and CYP2C9. Cells are treated with the compound at various concentrations, and the production of EETs is measured using mass spectrometry or ELISA. The compound's effects on cellular functions such as vascular tone, inflammation, and renal function may be assessed. |
| Animal Protocol |
Animal/Disease Models: Sixweeks old male stroke-prone spontaneously hypertensive rats (SHRSP)[3]
Doses: 20 mg/kg/day Route of Administration: intravenously (iv) Experimental Results: Treatment had negligible effects on systolic blood pressure (SBP) in saline-drinking SHRSP after 1 week, 160 vs. 167 mmHg, or 2 weeks of treatment, 171 vs. 175 mmHg, for vehicle vs. MS-PPOH, respectively. In vivo animal studies for MS-PPOH typically involve administration of the compound to rodents to study cardiovascular and renal function. The compound may be administered via intravenous or intraperitoneal injection. Following treatment, blood pressure, renal function, and inflammatory markers are assessed. The compound's ability to block EET formation and its effects on physiological processes are evaluated. |
| ADME/Pharmacokinetics |
As a small-molecule inhibitor, the pharmacokinetic properties of MS-PPOH would depend on its physicochemical characteristics. The compound has a molecular weight of 327.44 and a molecular formula of C16H25NO4S. Detailed PK parameters such as half-life, bioavailability, and tissue distribution are not available in the public domain. For research purposes, the compound is typically stored at -20°C.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for MS-PPOH in the available literature. As a research chemical, the compound is intended for laboratory use only and should be handled with standard safety precautions. Toxicity studies would be required if the compound were to be developed further for therapeutic applications. The compound is supplied with a purity of 98.42%.
|
| References |
|
| Additional Infomation |
Inhibition of arachidonic acid epoxidation in rat kidney microsomes
MS-PPOH is a potent and selective inhibitor of CYP2C8 and CYP2C9 with IC50 values of 15 μM and 11 μM, respectively. The compound is used to study vascular tone regulation, inflammation, and renal function by blocking EET formation. MS-PPOH has a molecular formula of C16H25NO4S and a molecular weight of 327.44. It is stored at -20°C. |
| Molecular Formula |
C16H21NO4S
|
|---|---|
| Molecular Weight |
323.41
|
| Exact Mass |
327.15
|
| CAS # |
206052-02-0
|
| PubChem CID |
10087567
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Index of Refraction |
1.517
|
| LogP |
3.16
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
486
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(=O)NC(=O)CCCCCC1=CC=CC=C1OCC#C
|
| InChi Key |
REUHFEYPDFRRGJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H21NO4S/c1-3-13-21-15-11-8-7-10-14(15)9-5-4-6-12-16(18)17-22(2,19)20/h1,7-8,10-11H,4-6,9,12-13H2,2H3,(H,17,18)
|
| Chemical Name |
N-methylsulfonyl-6-(2-prop-2-ynoxyphenyl)hexanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 200 mg/mL (618.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0921 mL | 15.4603 mL | 30.9205 mL | |
| 5 mM | 0.6184 mL | 3.0921 mL | 6.1841 mL | |
| 10 mM | 0.3092 mL | 1.5460 mL | 3.0921 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
